Expression, identification and biological effects of a novel VPAC2-specific agonist with high stability and bioactivity

Acta Biochimica et Biophysica Sinica

Volumn 42, Issue 1, 2010, Pages 21-29

  Ma, Yi ^a   Ma, Min ^b   Dai, Yun ^a   Hong, An ^a  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Biological effect; Expression; Identification; Recombinant agonist; Type 2 diabetes; VPAC2

Indexed keywords

ANTIDIABETIC AGENT; IMMUNOGLOBULIN G; PEPTIDE FRAGMENT; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADIPOCYTE; ANIMAL; ARTICLE; BINDING COMPETITION; CHO CELL; CRICETULUS; DRUG EFFECT; DRUG POTENTIATION; GENETICS; GLUCOSE BLOOD LEVEL; HAMSTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; RAT; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; SPRAGUE DAWLEY RAT;

ADIPOCYTES; ANIMALS; BINDING, COMPETITIVE; BLOOD GLUCOSE; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CRICETULUS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN G; MICE; MICE, INBRED ICR; MUTAGENESIS, SITE-DIRECTED; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; SIGNAL TRANSDUCTION;

MUS;

EID: 73549092721     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmp106     Document Type: Article

References (35)

1. Laburthe M, Couvineau A and Marie JC. VPAC receptors for VIP and PACAP. Receptors Channels 2002, 8: 137-153.
2. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J and Martinez C. VIP-PACAP system in immunity. Annu NY Acad Sci 2006, 1070: 51-74.
3. Sherwood NM, Krueckl SL and McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 2000, 21: 619-670.
4. Vaudry H and Laburthe M. VIP, PACAP, and related peptides. From gene to therapy. Annu NY Acad Sci 2006, 1070: 1-633.
5. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR and Rawlings SR, et al. International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998, 50: 265-270. (Pubitemid 28304027)
6. Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J and Dela Cruz F, et al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal, a potential therapy for type 2 diabetes. Diabetes 2002, 51: 1453-1460.
7. Yokota C, Kawai K, Ohashi S, Watanabe Y and Yamashita K. PACAP stimulates glucose output from the perfused rat liver. Peptides 1995, 16: 55-60.
8. Riddle MC and Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006, 29: 435-449.
9. Arulmozhi DK and Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 2006, 28: 96-108.
10. Pozo D. VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Med 2003, 9: 211-217.
11. Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M and Robberecht P. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor. Peptides 2000, 21: 1543-1549.
12. Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P and Waelbroeck M. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC2-selective ligands. Mol Pharmacol 1999, 56: 1280-1287.
13. Yu R, Xie Q, Dai Y, Gao Y, Zhou T and Hong A. Intein-mediated rapid purification and characterization of a novel recombinant agonist for VPAC2. Peptides 2006, 27: 1359-1366.
14. Yu RJ, Tam NL, Gao Y, Zeng ZH, Zhou TH and Hong A. A novel recombinant, VPAC2-selective agonist enhancing insulin release and glucose disposal. Acta Pharmacol Sin 2007, 28: 526-533.
15. Yung SL, Dela Cruz F, Hamren S, Zhu J, Tsutsumi M, Bloom JW and Caudle M, et al. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem 2003, 278: 10273-10281.
16. Ma Y, Yu R, Zeng L, Xie S and Hong A. Cloning and expression of the new gene recombinant RMBAY against type-2 diabetes and its production optimization. Chin Biotech 2009, 29: 17-21.
17. Osborne MJ, Su Z, Sridaran V and Ni F. Efficient expression of isotopically labeled peptides for high resolution NMR studies: application to the Cdc42/Rac binding domains of virulent kinases in Candida albicans. J Biomol NMR 2003, 26: 317-326.
18. Dawson PE and Kent SB. Synthesis of native proteins by chemical ligation. Annu Rev Biochem 2000, 69: 923-960.
19. Ma Y, Li H and Zhou T. Expression of gene recombinant GLP-1 derived polypeptide and its purification and identification. Chin Biotech 2009, 29: 1-6.
20. Lin P, Ye X and Ng TB. Purification of melibiose-binding lectins from two cultivars of Chinese black soybeans. Acta Biochim Biophys Sin 2009, 40: 1029-1038.
21. Gill SC and von Hippel PH. Calculation of protein extinction coeficients from amino acid sequence data. Anal Biochem 1989, 182: 319-326.
22. Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J and Waelbroeck M, et al. Development of high affinity selective VIP1 receptor agonists. Peptides 1997, 18: 1539-1545.
23. Nelson BA, obinson KA and Buse MG. High glucose and glucosamine induce insulin resistance via different mechanisms in 3T3-L1 adipocytes. Diabetes 2000, 49: 981-991.
24. Cui X, Song B, Hou L, Wei Z and Tang J. High expression of osteoglycin decreases the metastatic capability of mouse hepatocarcinoma Hca-F cells to lymph nodes. Acta Biochim Biophys Sin 2008, 40: 349-355.
25. Marx V. Watching peptide drugs grow up. C&EN News 2005, 83: 17-24.
26. Wang X, Li D and Gao C. Effect of APBMV on large intestine cancer LoVo cells and its synergetic effect with chemotherapy drugs. Prac J Med Pharm 2003, 20: 45-46.
27. Liu Z and Wang W. Effects of troxerutin and cerebroprotein hydrolysate in treatment of acute cer2 ebral embolism. Chin J Mod Med 2007, 4: 230-231.
28. Brown DL and Frank JE. Diagnosis and management of syphilis. Am Fam Physician 2003, 68: 283-290.
29. Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R and Ahlers J, et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 1999, 13: 2003-2012.
30. Wang Y, Su X, Wang F, Yu H, Chang S and Yang W. Induction of specific CTLs in BALB/c mice by chiral MUC1 synthetic peptide vaccine. J Fourth Mil Med Univ 2004, 25: 1452-1455.
31. Merika M and Thanos D. Enhanceosomes. Curr Opin Genet Dev 2001, 11: 205-208.
32. Costes S, Broca C, Bertrand G, Lajoix AD, Bataille D, Bockaert J and Dalle S. ERK1/2 control phosphorylation and protein level of cAMP-responsive element-binding protein: a key role in glucose-mediated pancreatic b-cell survival. Diabetes 2006, 55: 2220-2230.
33. Dugani CB, Randhawa VK, Cheng AP, Patel N and Klip A. Selective regulation of the perinuclear distribution of glucose transporter 4 (GLUT4) by insulin signals in muscle cells. Eur J Cell Biol 2008, 87: 337-351.
34. Li Y, Wang P, Xu J, Gorelick F, Yamazaki H, Andrews N and Desir GV. Regulation of insulin secretion and GLUT4 trafficking by the calcium sensor synaptotagmin VII. Biochem Biophys Res Commun 2007, 362: 658-664.
35. Funaki M, Benincasa K and Randhawa PK. Peptide rescues GLUT4 recruitment, but not GLUT4 activation, in insulin resistance. Biochem Biophys Res Commun 2007, 360: 891-896.